Supplementary Table 4 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer Harshabad Singh , Pranshu Sahgal , Kevin Kapner , Steven M. Corsello , Hersh Gupta , Rahul Gujrathi , Yvonne Y. Li , Andrew D. Cherniack , Raquelle El Alam , , Elizabeth Andrews , Annette Lee , Chetan Nambiar , Alison M. Hannigan , Joshua Remland , Lauren Brais , Meghan E. Leahy , Douglas A. Rubinson , Benjamin L. Schlechter , Matthew Meyerson , Yanan Kuang , Cloud P. Paweletz , Jessica K. Lee , Julia C.F. Quintanilha , Andrew J. Aguirre , Kimberly J. Perez , Brandon M. Huffman , Humberto Rossi , Thomas A. Abrams , Sheheryar Kabraji , Livio Trusolino , Andrea Bertotti , Ewa T. Sicinska , Aparna R. Parikh , Brian M. Wolpin , Alexa B. Schrock , Marios Giannakis , Kimmie Ng , Jeffrey A. Meyerhardt , Jason L. Hornick , Nilay S. Sethi , James M. Cleary crossref（2024）
摘要
Supplementary Table 4. Impact of clinical, genomic features on time to treatment discontinuation for HER2 directed therapy in the FH-FMI CGDB.
更多 查看译文
AI 理解论文
溯源树
样例
